Destiny Pharma has two novel programs for infection prevention using biotherapeutic products. These programmes are harnessing the potential benefits of naturally occurring bacteria as medicines through their interaction with the human microbiome and broader human biological systems.
In November 2020, Destiny Pharma acquired the global rights to a clinical stage asset, NTCD-M3, for the prevention of C. difficile infection (CDI) recurrence. NTCD-M3 is a naturally occurring, non-toxigenic strain of C. difficile that can “out compete” with the dangerous toxic strains of C. difficile in the gut and thereby greatly reduce the damage caused by the toxins produced by toxigenic C. difficile.
Destiny Pharma also has a COVID-19/influenza preclinical programme in collaboration with SporeGen Limited to co-develop SporeGen’s SPOR-COV™ product as a novel, preventive treatment for COVID-19. Destiny and SporeGen secured funding for the research program via an Innovate UK grant award of £800,000 in 2020. The SPOR‑COV product consists of a proprietary formulation of Bacillus bacteria that will be administered nasally as a spray.